Clinical Trial Update: An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma

View source ↗

Summary

This update notes that the Expanded Access Program for VO (RP1) in combination with nivolumab for advanced melanoma is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• VO (RP1)
• nivolumab (nivolumab)

Snippet

Sponsor: Replimune, Inc. | Conditions: Advanced Melanoma | Status: NO_LONGER_AVAILABLE